Analisi costo-efficacia di cinacalcet più terapia standard versus terapia standard nel trattamento dei pazienti in dialisi con iperparatiroidismo secondario
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cohen EP, Moulder JE. Parathyroidectomy in chronic renal failure: has medical care reduced the need for surgery? Nephron 2002; 89: 271–3
Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997; 29: 862–5
United States Renal Data System. Cardiovascular report [online]. Available from URL: http://www.usrds.org/adr.htm [Accessed 2006 Aug 2]
European Dialysis and Transplantation Association/European Renal Association (EDTA-ERA). Registry Annual Report 2001. http://www.era-edta.org/erafset.htm
Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2006; 1: 246–55
National Kidney Foundation, Inc. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 8: vitamin D therapy in chronic kidney disease patients. Guideline 8b: vitamin D therapy in patients on dialysis (chronic kidney disease stage 5) [online]. Available from URL: http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm and http://www.kidney.org/professionals/kdoqi/guidelines_bone/Images/Algorithm5L [Accessed 2006 Aug 2]
Diaz-Corte C, Naves Diaz ML, Gomez Alonso C, et al. Prevention, diagnosis and treatment of renal osteodystrophy in Spain: preliminary results from a multicentre enquiry. Nephrol Dial Transplant 1998; 13 (Suppl. 3): 51–6
Gallieni M, Cucciniello E, D’Amaro E, et al. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol 2002; 15: 165–70
Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83
Ganesh SK, Stack AG, Lewin NW, et al. Association of elevated serum PO(4), Ca?PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–8
National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(S3): 1–202
Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44 (5 Suppl. 2): 34–8
Locatelli F, Pontoriero G, Limardo M, et al. I calciomimetici nella terapia dell’iperparatiroidismo primario e secondario. Attualità Nefrologiche & Dialitiche 2005
Bandini S. Osteodistrofia renale: prevenzione e trattamento. II Parte. Giornale di Tecniche Nefrologiche & Dialitiche 2006; XVIII: 6–13
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1–266
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford: Oxford University Press, 2005
Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; (85): S111–4
Moe SM, Reslerova M, Ketteler M. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005; 676: 2295–304
http://www.emea.europa.eu/humandocs/Humans/EPAR/mimpara/mimpara.htm
Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760–71
Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: iii, xi–xiii, 1–167